NCT04443907View on ClinicalTrials.gov

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

January 6, 2025

Study Completion Date

January 6, 2025

Conditions
Sickle Cell Disease
Interventions
BIOLOGICAL

OTQ923

Single intravenous infusion of OTQ923 cell suspension

BIOLOGICAL

OTQ923

Single intravenous infusion of OTQ923, based on review of data from Part A by Health agencies after a formal interim analysis

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Ctr, New York

60637

University of Chicago, Chicago

38105-3678

St Jude Children's Research Hospital, Memphis

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY